Regulatory information – 1.7% and 1.6% increase of pharmacovigilance fees from 1 November 2020
News
Human
Fees
Pharmacovigilance
Pharmacovigilance fees payable to the European Medicines Agency(EMA) by applicants and marketing authorisation holders increase by 1.7% and 1.6% as of 1 November 2020, to reflect the inflation rate adjustments of 2018 and 2019 respectively.
Full details of the new fee levels are available in Commission Regulation (EU) No 2020/1431 amending Regulation (EU) No 658/2014 and in the Explanatory note on pharmacovigilance fees payable to EMA (as of 4 October 2023).